Compare TNET & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TNET | IDYA |
|---|---|---|
| Founded | 1988 | 2015 |
| Country | United States | United States |
| Employees | 2700 | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.9B |
| IPO Year | 2000 | 2019 |
| Metric | TNET | IDYA |
|---|---|---|
| Price | $37.83 | $34.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 16 |
| Target Price | ★ $65.80 | $51.21 |
| AVG Volume (30 Days) | 556.3K | ★ 707.7K |
| Earning Date | 05-15-2026 | 05-19-2026 |
| Dividend Yield | ★ 2.96% | N/A |
| EPS Growth | N/A | ★ 61.90 |
| EPS | ★ 3.20 | N/A |
| Revenue | ★ $5,010,000,000.00 | $218,710,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.30 | $213.03 |
| P/E Ratio | $11.91 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $33.67 | $13.45 |
| 52 Week High | $88.56 | $39.28 |
| Indicator | TNET | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 54.97 |
| Support Level | $33.67 | $32.85 |
| Resistance Level | $39.10 | $36.38 |
| Average True Range (ATR) | 1.74 | 1.34 |
| MACD | 0.81 | 0.19 |
| Stochastic Oscillator | 70.31 | 73.93 |
Trinet Group Inc provides human resources solutions for small and medium-sized businesses through technology-enabled services. Its offerings include human capital expertise, employee benefits such as health insurance and retirement plans, payroll and payroll tax administration, risk mitigation, and compliance consulting. The company provides its services through professional employer organization (PEO) services delivered via a co-employment model, as well as administrative services organization (ASO) offerings. The majority of the company's revenue is derived from the insurance-related billings and administrative fees collected from PEO clients.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.